Significant Milestone Reached in ACL Digital Pathology Study

Key points

• Optiscan successfully imaged over 80 cases using InForm™ platform
• Study conducted at ACL's pathology lab in Western Australia
• Collaboration aims to optimize workflow and support regulatory submissions

Full summary

Optiscan Imaging Ltd (ASX: OIL) has achieved a significant milestone in its digital pathology study with Australian Clinical Labs (ACL), successfully imaging more than 80 cases using its InForm platform in a real-world pathology environment. The study, conducted at ACL's flagship laboratory in Western Australia, is evaluating the performance of InForm in a high-throughput setting across a range of tissue types and clinical use cases. The collaboration is generating real-world data to support workflow optimization, pathologist training, and future regulatory submissions. By leveraging ACL's extensive pathology network, Optiscan is able to validate the technology's performance under a diverse set of conditions, enhancing its readiness for broader commercial deployment.